Durvalumab Plus Chemo Improves Survival for Small Cell Lung Cancer - Cancer Currents Blog National Cancer Institute sent this bulletin at 11/01/2019 10:35 AM EDT Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer 10/31/2019 A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.
